Combination pill treatment for advanced ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two oral medications (fluzopril and apatinib) as maintenance therapy after chemotherapy, for patients with platinum-resistant ovarian cancer. The goal is to see if this combo helps keep the cancer from growing longer than usual.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and 18 years of age or older.
- You have a specific type of ovarian, fallopian tube, or peritoneal cancer that is high grade or moderate to poorly differentiated.
- Your cancer progressed within 6 months after your last platinum-based chemo (like carboplatin or cisplatin).
- You have had at least 3 rounds of chemo and are not currently progressing; you can start this trial within 6 weeks after your last chemo dose.
- You must be able to provide a stored tumor tissue sample (FFPE block).
- Your overall health is good (ECOG score 0 or 1) and your blood, liver, and kidney function meet the trial's requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two targeted therapies, fluzoparib (a PARP inhibitor) and apatinib (a blood vessel blocker), as maintenance treatment after initial chemotherapy for advanced ovarian cancer. The goal is to see if this combination helps keep the cancer from coming back longer than usual.
This trial tests two oral medications (fluzoparib and apatinib) taken daily as maintenance therapy after your ovarian cancer has responded to chemotherapy. The goal is to keep the cancer from returning for as long as possible.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
Hear when a new Ovarian Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.